Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

• Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes Association (ADA) Scientific Sessions.^1,2
• Oral amycretin phase 1 data on the safety, tolerability and weight loss potential in people with overweight or obesity was also published in The Lancet.³
• Findings from the clinical trials indicate amycretin appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.^1,2,3
  
  

Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85^th Scientific Sessions in Chicago, US.¹ Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.^1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule.

The published and presented results from the once-weekly subcutaneous amycretin phase 1b/2a clinical trial showed that participants who received the treatment demonstrated significantly greater weight loss across the full range of doses investigated compared to placebo. Data being presented at ADA were collected from two parts of the trial; dose escalation (amycretin 60 mg), and dose escalation and maintenance (amycretin 20 mg, 5 mg and 1.25 mg).^1,2 No plateauing in weight reduction was observed at the end of treatment (ranging from 20 to 36 weeks) with all tested doses, suggesting that a longer treatment duration may potentially contribute to additional weight loss.^1,2

Estimated mean change in body weight from baseline with once-weekly subcutaneous (SC) amycretin: ^1,2 *

Dose        Treatment        % Weight change        % Weight change
                 duration          (SC amycretin)                (placebo)

60 mg        36 weeks           -24.3%                         -1.1%